Amanda Smith, DPhil

Cambridge, United Kingdom
Amanda Smith is the CEO of Pencil Biosciences Ltd, a UK-based start-up company, developing a fully synthetic, non-CRISPR gene editing technology.

Amanda is also Head of Intellectual Property at Epitopea Inc, a transatlantic cancer immunotherapeutic company.

Previously, Amanda was the Head of IP and Licensing at Horizon Discovery and Dharmacon, both PerkinElmer companies, that have a focus on gene editing and RNA.

Before joining Horizon Discovery, Amanda worked at Sanofi where she had a medical innovation role in the Consumer Healthcare Division.

Originally a research scientist in the field of neurophysiology, Amanda subsequently spent seven years at The University of Queensland, Australia in technology transfer.

Amanda is a registered patent and trademark attorney and has a PhD in neurophysiology from the University of Oxford, a Bachelor’s degree in pharmacology, and a Master’s degree in IP law.
Speaking In
4:15 PM - 5:15 PM (PDT)
Tuesday, June 14
Scientific breakthroughs during the pandemic are driving a lot of optimism around mRNA technology,…